| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 16 | 2022 | 447 | 3.970 |
Why?
|
| Emodin | 9 | 2022 | 21 | 3.670 |
Why?
|
| Macrophages | 28 | 2023 | 647 | 3.370 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 10 | 2018 | 34 | 2.890 |
Why?
|
| Atherosclerosis | 16 | 2022 | 204 | 2.550 |
Why?
|
| Breast Neoplasms | 10 | 2022 | 1536 | 2.340 |
Why?
|
| Inflammation | 16 | 2023 | 1030 | 2.010 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 1173 | 1.890 |
Why?
|
| Mice | 59 | 2023 | 8474 | 1.710 |
Why?
|
| Toll-Like Receptor 4 | 8 | 2018 | 114 | 1.710 |
Why?
|
| Apolipoproteins E | 9 | 2015 | 92 | 1.710 |
Why?
|
| Tumor Microenvironment | 9 | 2022 | 213 | 1.700 |
Why?
|
| Receptors, LDL | 13 | 2020 | 72 | 1.690 |
Why?
|
| Cell Movement | 9 | 2021 | 630 | 1.620 |
Why?
|
| Mice, Inbred C57BL | 34 | 2023 | 2791 | 1.510 |
Why?
|
| Animals | 72 | 2023 | 20881 | 1.430 |
Why?
|
| Antineoplastic Agents | 7 | 2022 | 1070 | 1.400 |
Why?
|
| Toll-Like Receptor 2 | 5 | 2015 | 34 | 1.380 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 300 | 1.240 |
Why?
|
| Cell Proliferation | 10 | 2021 | 1174 | 1.210 |
Why?
|
| Serine Endopeptidases | 6 | 2017 | 50 | 1.210 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 508 | 1.120 |
Why?
|
| Cell Line, Tumor | 14 | 2022 | 1851 | 1.040 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 331 | 1.000 |
Why?
|
| Cholesterol | 8 | 2020 | 331 | 0.960 |
Why?
|
| Proprotein Convertases | 5 | 2015 | 8 | 0.850 |
Why?
|
| Apoptosis | 14 | 2022 | 1641 | 0.840 |
Why?
|
| Mice, Knockout | 21 | 2020 | 1692 | 0.830 |
Why?
|
| Myocytes, Smooth Muscle | 3 | 2020 | 144 | 0.830 |
Why?
|
| Autophagy | 7 | 2022 | 208 | 0.810 |
Why?
|
| Lipopolysaccharides | 6 | 2016 | 455 | 0.790 |
Why?
|
| Ribonucleases | 4 | 2013 | 25 | 0.790 |
Why?
|
| Signal Transduction | 16 | 2022 | 2689 | 0.790 |
Why?
|
| Microfilament Proteins | 1 | 2022 | 102 | 0.770 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2020 | 24 | 0.760 |
Why?
|
| GTPase-Activating Proteins | 1 | 2021 | 21 | 0.750 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 95 | 0.750 |
Why?
|
| Cell Communication | 3 | 2020 | 116 | 0.730 |
Why?
|
| Tristetraprolin | 1 | 2020 | 9 | 0.730 |
Why?
|
| Interleukin-1beta | 4 | 2023 | 88 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2020 | 331 | 0.710 |
Why?
|
| Reactive Oxygen Species | 4 | 2023 | 499 | 0.700 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 61 | 0.690 |
Why?
|
| Myeloid Cells | 3 | 2015 | 57 | 0.690 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 84 | 0.680 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2020 | 223 | 0.680 |
Why?
|
| Receptors, Virus | 1 | 2019 | 20 | 0.680 |
Why?
|
| Inflammation Mediators | 5 | 2021 | 244 | 0.660 |
Why?
|
| Triterpenes | 2 | 2016 | 40 | 0.630 |
Why?
|
| Bone Marrow | 3 | 2020 | 168 | 0.630 |
Why?
|
| Drugs, Chinese Herbal | 3 | 2015 | 15 | 0.630 |
Why?
|
| Lipoproteins, HDL | 4 | 2018 | 113 | 0.610 |
Why?
|
| Lipids | 4 | 2022 | 298 | 0.590 |
Why?
|
| Female | 31 | 2022 | 38074 | 0.580 |
Why?
|
| Humans | 56 | 2023 | 68618 | 0.580 |
Why?
|
| Cell Polarity | 2 | 2019 | 49 | 0.570 |
Why?
|
| Hyperlipidemias | 2 | 2014 | 90 | 0.560 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2014 | 20 | 0.560 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 4 | 2020 | 45 | 0.540 |
Why?
|
| Down-Regulation | 2 | 2019 | 447 | 0.540 |
Why?
|
| Immunologic Memory | 1 | 2016 | 75 | 0.520 |
Why?
|
| Cell Line | 11 | 2021 | 1752 | 0.500 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 375 | 0.500 |
Why?
|
| Shock, Septic | 1 | 2015 | 101 | 0.480 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2014 | 84 | 0.460 |
Why?
|
| Disease Models, Animal | 14 | 2022 | 2550 | 0.460 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 306 | 0.440 |
Why?
|
| NF-kappa B | 5 | 2020 | 432 | 0.440 |
Why?
|
| Cells, Cultured | 10 | 2021 | 2673 | 0.440 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2015 | 317 | 0.440 |
Why?
|
| Tumor Burden | 5 | 2022 | 132 | 0.420 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 217 | 0.410 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 304 | 0.410 |
Why?
|
| MAP Kinase Signaling System | 3 | 2021 | 247 | 0.400 |
Why?
|
| Plant Extracts | 1 | 2013 | 122 | 0.400 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2021 | 135 | 0.400 |
Why?
|
| Plaque, Atherosclerotic | 4 | 2022 | 125 | 0.400 |
Why?
|
| Neoplasms | 3 | 2022 | 1667 | 0.390 |
Why?
|
| Magnoliopsida | 1 | 2011 | 5 | 0.390 |
Why?
|
| Mice, Inbred BALB C | 3 | 2020 | 532 | 0.390 |
Why?
|
| Kruppel-Like Transcription Factors | 3 | 2017 | 25 | 0.380 |
Why?
|
| RNA, Messenger | 6 | 2020 | 1664 | 0.380 |
Why?
|
| Macrophages, Peritoneal | 4 | 2015 | 67 | 0.380 |
Why?
|
| Cytokines | 7 | 2022 | 866 | 0.380 |
Why?
|
| Biomarkers | 7 | 2021 | 1593 | 0.380 |
Why?
|
| Endothelial Cells | 4 | 2020 | 384 | 0.370 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2021 | 126 | 0.350 |
Why?
|
| Bone Marrow Transplantation | 4 | 2014 | 149 | 0.350 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 240 | 0.330 |
Why?
|
| Liver | 7 | 2021 | 1118 | 0.330 |
Why?
|
| Adipose Tissue | 3 | 2020 | 221 | 0.330 |
Why?
|
| Chemokine CCL2 | 5 | 2017 | 101 | 0.320 |
Why?
|
| Th17 Cells | 3 | 2014 | 116 | 0.320 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 209 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2022 | 756 | 0.310 |
Why?
|
| Pneumonia, Viral | 2 | 2021 | 154 | 0.300 |
Why?
|
| Monocytes | 4 | 2022 | 210 | 0.290 |
Why?
|
| PPAR gamma | 4 | 2021 | 95 | 0.290 |
Why?
|
| Protein Structure, Tertiary | 5 | 2015 | 322 | 0.290 |
Why?
|
| Mice, Nude | 2 | 2020 | 294 | 0.290 |
Why?
|
| Oxidative Stress | 4 | 2015 | 718 | 0.280 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 299 | 0.280 |
Why?
|
| Neovascularization, Pathologic | 2 | 2019 | 183 | 0.280 |
Why?
|
| Fibroblasts | 4 | 2021 | 902 | 0.270 |
Why?
|
| Proprotein Convertase 9 | 5 | 2015 | 14 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 852 | 0.270 |
Why?
|
| Methionine Sulfoxide Reductases | 2 | 2015 | 2 | 0.260 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2011 | 194 | 0.260 |
Why?
|
| Fluorouracil | 2 | 2022 | 130 | 0.250 |
Why?
|
| Acyltransferases | 2 | 2022 | 40 | 0.240 |
Why?
|
| Phosphorylation | 4 | 2020 | 1200 | 0.240 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2015 | 87 | 0.230 |
Why?
|
| RAW 264.7 Cells | 3 | 2021 | 42 | 0.230 |
Why?
|
| Male | 22 | 2022 | 37321 | 0.230 |
Why?
|
| Interleukin-6 | 5 | 2021 | 330 | 0.220 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 307 | 0.220 |
Why?
|
| Th1 Cells | 2 | 2014 | 101 | 0.220 |
Why?
|
| Hepatocytes | 3 | 2015 | 205 | 0.220 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 22 | 0.220 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 561 | 0.210 |
Why?
|
| Quercetin | 1 | 2022 | 16 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2022 | 332 | 0.210 |
Why?
|
| Antioxidants | 2 | 2022 | 304 | 0.210 |
Why?
|
| Inflammasomes | 1 | 2023 | 39 | 0.210 |
Why?
|
| Cysteic Acid | 1 | 2022 | 2 | 0.210 |
Why?
|
| Cell Cycle | 2 | 2014 | 312 | 0.210 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 41 | 0.210 |
Why?
|
| Vesicular Stomatitis | 1 | 2022 | 1 | 0.210 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2020 | 160 | 0.200 |
Why?
|
| Hep G2 Cells | 4 | 2019 | 68 | 0.200 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 219 | 0.200 |
Why?
|
| Oncolytic Virotherapy | 1 | 2022 | 15 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2017 | 626 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2022 | 17 | 0.200 |
Why?
|
| Macrophage Activation | 3 | 2020 | 75 | 0.200 |
Why?
|
| Crystallography, X-Ray | 2 | 2013 | 190 | 0.200 |
Why?
|
| ATP Binding Cassette Transporter 1 | 3 | 2019 | 13 | 0.200 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2022 | 160 | 0.200 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 40 | 0.200 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 434 | 0.200 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 20 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2013 | 226 | 0.200 |
Why?
|
| Resorcinols | 1 | 2021 | 8 | 0.190 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2019 | 44 | 0.190 |
Why?
|
| Transfection | 4 | 2019 | 782 | 0.190 |
Why?
|
| Mucositis | 1 | 2021 | 9 | 0.190 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 81 | 0.190 |
Why?
|
| Peptides | 2 | 2015 | 455 | 0.190 |
Why?
|
| Blotting, Western | 2 | 2014 | 954 | 0.190 |
Why?
|
| Rats | 5 | 2017 | 5300 | 0.190 |
Why?
|
| Interleukin-4 | 2 | 2022 | 69 | 0.190 |
Why?
|
| Cell Adhesion | 3 | 2020 | 324 | 0.190 |
Why?
|
| HEK293 Cells | 5 | 2013 | 326 | 0.180 |
Why?
|
| Autophagy-Related Proteins | 2 | 2021 | 17 | 0.180 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 7 | 0.180 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 56 | 0.180 |
Why?
|
| Coronavirus | 1 | 2020 | 16 | 0.180 |
Why?
|
| Diet, High-Protein | 1 | 2020 | 1 | 0.180 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 111 | 0.180 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 742 | 0.180 |
Why?
|
| Coculture Techniques | 1 | 2020 | 147 | 0.180 |
Why?
|
| Mastectomy | 1 | 2020 | 57 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 129 | 0.180 |
Why?
|
| RNA Stability | 1 | 2020 | 55 | 0.180 |
Why?
|
| Scavenger Receptors, Class B | 2 | 2018 | 18 | 0.180 |
Why?
|
| Protein Engineering | 3 | 2011 | 35 | 0.180 |
Why?
|
| Biological Assay | 2 | 2021 | 88 | 0.170 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 1293 | 0.170 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2020 | 114 | 0.170 |
Why?
|
| Enzyme Activation | 4 | 2015 | 791 | 0.170 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 166 | 0.170 |
Why?
|
| Lipoproteins | 1 | 2020 | 161 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2022 | 254 | 0.170 |
Why?
|
| Autophagy-Related Protein 5 | 2 | 2016 | 11 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 118 | 0.160 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 245 | 0.160 |
Why?
|
| Escherichia coli | 3 | 2015 | 368 | 0.160 |
Why?
|
| Sphingolipids | 1 | 2022 | 337 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 214 | 0.160 |
Why?
|
| Obesity | 3 | 2022 | 1076 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 216 | 0.160 |
Why?
|
| Computational Biology | 1 | 2020 | 190 | 0.160 |
Why?
|
| Focal Adhesions | 1 | 2018 | 25 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2018 | 384 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 332 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2E1 | 2 | 2015 | 11 | 0.160 |
Why?
|
| Transcription Factors | 2 | 2013 | 753 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2018 | 97 | 0.150 |
Why?
|
| Dendritic Cells | 1 | 2020 | 201 | 0.150 |
Why?
|
| Cell Survival | 3 | 2016 | 901 | 0.150 |
Why?
|
| Weight Loss | 1 | 2020 | 319 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 21 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 234 | 0.150 |
Why?
|
| Trehalose | 1 | 2017 | 3 | 0.150 |
Why?
|
| CD11b Antigen | 2 | 2014 | 47 | 0.150 |
Why?
|
| Aryldialkylphosphatase | 2 | 2015 | 11 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2016 | 397 | 0.140 |
Why?
|
| Antigens, Ly | 2 | 2014 | 14 | 0.140 |
Why?
|
| Body Weight | 4 | 2022 | 554 | 0.140 |
Why?
|
| Peroxiredoxins | 1 | 2016 | 34 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2017 | 114 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2017 | 94 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 231 | 0.140 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 236 | 0.140 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2021 | 2083 | 0.140 |
Why?
|
| Lung | 2 | 2021 | 849 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.140 |
Why?
|
| Diet, Western | 1 | 2016 | 17 | 0.140 |
Why?
|
| Interferon Regulatory Factors | 1 | 2016 | 24 | 0.140 |
Why?
|
| Nanocapsules | 1 | 2016 | 10 | 0.130 |
Why?
|
| Necrosis | 2 | 2014 | 239 | 0.130 |
Why?
|
| Epigenomics | 1 | 2016 | 29 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 597 | 0.130 |
Why?
|
| Hepatitis | 1 | 2015 | 25 | 0.130 |
Why?
|
| Cysteamine | 1 | 2015 | 5 | 0.130 |
Why?
|
| Membrane Microdomains | 1 | 2015 | 32 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 175 | 0.130 |
Why?
|
| Photochemotherapy | 1 | 2016 | 59 | 0.130 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 126 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 118 | 0.130 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 271 | 0.130 |
Why?
|
| Lysosomes | 3 | 2022 | 136 | 0.130 |
Why?
|
| Binding Sites | 2 | 2020 | 631 | 0.130 |
Why?
|
| NADPH Oxidases | 1 | 2015 | 80 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2015 | 7 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1745 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 301 | 0.120 |
Why?
|
| Mice, Inbred ICR | 1 | 2015 | 44 | 0.120 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 88 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 160 | 0.120 |
Why?
|
| Mutagenesis | 2 | 2011 | 60 | 0.120 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2014 | 19 | 0.120 |
Why?
|
| Nitroso Compounds | 1 | 2014 | 16 | 0.120 |
Why?
|
| STAT6 Transcription Factor | 1 | 2014 | 11 | 0.120 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 78 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2016 | 597 | 0.120 |
Why?
|
| Pressure Ulcer | 1 | 2015 | 40 | 0.120 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 77 | 0.120 |
Why?
|
| Glomerular Mesangium | 1 | 2014 | 53 | 0.120 |
Why?
|
| Body Temperature | 1 | 2015 | 116 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2017 | 384 | 0.120 |
Why?
|
| Gene Expression | 2 | 2020 | 770 | 0.120 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 35 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 71 | 0.120 |
Why?
|
| Diet, Atherogenic | 1 | 2014 | 6 | 0.120 |
Why?
|
| HMGB1 Protein | 1 | 2014 | 23 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 157 | 0.110 |
Why?
|
| Disease Progression | 2 | 2014 | 1038 | 0.110 |
Why?
|
| Estradiol | 1 | 2015 | 176 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 92 | 0.110 |
Why?
|
| Protein Binding | 3 | 2020 | 1027 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 140 | 0.110 |
Why?
|
| Hypoxia | 1 | 2014 | 169 | 0.110 |
Why?
|
| Dextran Sulfate | 3 | 2022 | 88 | 0.110 |
Why?
|
| Asthma | 1 | 2017 | 345 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 235 | 0.110 |
Why?
|
| Colitis | 1 | 2014 | 156 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2014 | 109 | 0.110 |
Why?
|
| Mutation | 2 | 2011 | 1213 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 88 | 0.110 |
Why?
|
| Xanthones | 1 | 2012 | 2 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 710 | 0.110 |
Why?
|
| Wound Healing | 1 | 2015 | 260 | 0.110 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2013 | 42 | 0.110 |
Why?
|
| Anemia | 1 | 2013 | 104 | 0.110 |
Why?
|
| Aldehydes | 1 | 2012 | 34 | 0.110 |
Why?
|
| Base Sequence | 2 | 2020 | 1015 | 0.110 |
Why?
|
| Virus Internalization | 1 | 2012 | 10 | 0.100 |
Why?
|
| Mice, Transgenic | 4 | 2017 | 1033 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 94 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 940 | 0.100 |
Why?
|
| Adipocytes | 1 | 2013 | 88 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2017 | 631 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 199 | 0.100 |
Why?
|
| Sepsis | 1 | 2015 | 233 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2012 | 90 | 0.100 |
Why?
|
| Skin | 1 | 2015 | 451 | 0.100 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 38 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2014 | 307 | 0.100 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2012 | 133 | 0.100 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2011 | 15 | 0.100 |
Why?
|
| Interleukin-10 | 2 | 2022 | 144 | 0.100 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 30 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2012 | 132 | 0.100 |
Why?
|
| Copper | 1 | 2012 | 149 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 82 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2013 | 222 | 0.090 |
Why?
|
| Spleen | 3 | 2021 | 301 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2012 | 114 | 0.090 |
Why?
|
| Apolipoprotein E3 | 2 | 2007 | 7 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2011 | 156 | 0.090 |
Why?
|
| Stilbenes | 1 | 2011 | 57 | 0.090 |
Why?
|
| Fetal Diseases | 1 | 2011 | 64 | 0.090 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 442 | 0.090 |
Why?
|
| Pregnancy in Diabetics | 1 | 2011 | 70 | 0.090 |
Why?
|
| Aged | 4 | 2021 | 14862 | 0.090 |
Why?
|
| Molecular Structure | 1 | 2011 | 397 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2014 | 738 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2011 | 215 | 0.090 |
Why?
|
| Homeostasis | 1 | 2011 | 291 | 0.090 |
Why?
|
| Phagocytosis | 1 | 2010 | 65 | 0.090 |
Why?
|
| Coronary Artery Disease | 2 | 2013 | 696 | 0.090 |
Why?
|
| Azoxymethane | 2 | 2022 | 28 | 0.080 |
Why?
|
| Fibrinogen | 1 | 2009 | 87 | 0.080 |
Why?
|
| Diet | 1 | 2013 | 514 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2009 | 114 | 0.080 |
Why?
|
| HeLa Cells | 3 | 2015 | 237 | 0.080 |
Why?
|
| Smad3 Protein | 2 | 2021 | 33 | 0.080 |
Why?
|
| Dimyristoylphosphatidylcholine | 2 | 2007 | 4 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 807 | 0.080 |
Why?
|
| Circular Dichroism | 2 | 2007 | 99 | 0.080 |
Why?
|
| Acute Disease | 2 | 2021 | 658 | 0.080 |
Why?
|
| Proteins | 1 | 2011 | 474 | 0.080 |
Why?
|
| Hydrolysis | 1 | 2008 | 144 | 0.080 |
Why?
|
| Fibrosis | 2 | 2021 | 371 | 0.070 |
Why?
|
| DNA Primers | 1 | 2008 | 302 | 0.070 |
Why?
|
| Membrane Proteins | 3 | 2018 | 617 | 0.070 |
Why?
|
| Estrogens | 2 | 2022 | 173 | 0.070 |
Why?
|
| Apolipoprotein E2 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 1083 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 1447 | 0.070 |
Why?
|
| Proteolysis | 2 | 2020 | 97 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2018 | 108 | 0.070 |
Why?
|
| Collagen | 2 | 2021 | 636 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2022 | 211 | 0.070 |
Why?
|
| Lentivirus | 2 | 2021 | 35 | 0.070 |
Why?
|
| HIV Infections | 1 | 2013 | 791 | 0.070 |
Why?
|
| Time Factors | 1 | 2014 | 4655 | 0.060 |
Why?
|
| Adiponectin | 2 | 2017 | 52 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2017 | 33 | 0.060 |
Why?
|
| Guanidine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2021 | 346 | 0.060 |
Why?
|
| Protein Denaturation | 1 | 2004 | 27 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2004 | 67 | 0.060 |
Why?
|
| Solubility | 1 | 2004 | 134 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 567 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2018 | 682 | 0.060 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2004 | 85 | 0.060 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2004 | 85 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2004 | 136 | 0.060 |
Why?
|
| Cross-Linking Reagents | 1 | 2004 | 80 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 231 | 0.060 |
Why?
|
| Receptors, CCR2 | 2 | 2015 | 9 | 0.060 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2022 | 2 | 0.050 |
Why?
|
| Lipid Peroxidation | 2 | 2014 | 94 | 0.050 |
Why?
|
| Acids | 1 | 2022 | 12 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2022 | 71 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 87 | 0.050 |
Why?
|
| Chryseobacterium | 1 | 2022 | 2 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1034 | 0.050 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 2022 | 1 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 137 | 0.050 |
Why?
|
| Polyesters | 1 | 2022 | 55 | 0.050 |
Why?
|
| Cachexia | 1 | 2022 | 54 | 0.050 |
Why?
|
| Feedback | 1 | 2022 | 90 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2022 | 62 | 0.050 |
Why?
|
| Flavonoids | 1 | 2022 | 109 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2004 | 546 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 65 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2022 | 99 | 0.050 |
Why?
|
| B7-1 Antigen | 1 | 2021 | 20 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 124 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2021 | 43 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2021 | 23 | 0.050 |
Why?
|
| Streptomyces | 1 | 2021 | 15 | 0.050 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2021 | 28 | 0.050 |
Why?
|
| Smad2 Protein | 1 | 2021 | 42 | 0.050 |
Why?
|
| Toxicity Tests, Subchronic | 1 | 2021 | 3 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2021 | 73 | 0.050 |
Why?
|
| Glucuronides | 1 | 2021 | 5 | 0.050 |
Why?
|
| Autophagosomes | 1 | 2021 | 6 | 0.050 |
Why?
|
| Molecular Conformation | 1 | 2021 | 128 | 0.050 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 2 | 2011 | 9 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2021 | 55 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2015 | 186 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 134 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 137 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 150 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 139 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 147 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 230 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 226 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2020 | 20 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2021 | 89 | 0.050 |
Why?
|
| Phylogeny | 1 | 2021 | 197 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1174 | 0.040 |
Why?
|
| Colon | 1 | 2021 | 168 | 0.040 |
Why?
|
| China | 1 | 2020 | 138 | 0.040 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2019 | 3 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 7 | 0.040 |
Why?
|
| Liver X Receptors | 1 | 2019 | 8 | 0.040 |
Why?
|
| Weight Gain | 1 | 2020 | 135 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 446 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 196 | 0.040 |
Why?
|
| Data Mining | 1 | 2019 | 45 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 396 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 370 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| Cyclin E | 1 | 2018 | 19 | 0.040 |
Why?
|
| Stress Fibers | 1 | 2018 | 10 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2021 | 295 | 0.040 |
Why?
|
| Probucol | 1 | 2018 | 1 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1851 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 86 | 0.040 |
Why?
|
| Fibronectins | 1 | 2018 | 130 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.040 |
Why?
|
| Hepatic Stellate Cells | 1 | 2018 | 53 | 0.040 |
Why?
|
| Sequestosome-1 Protein | 1 | 2017 | 12 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2016 | 45 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 52 | 0.040 |
Why?
|
| Copper Radioisotopes | 1 | 2016 | 5 | 0.030 |
Why?
|
| Theranostic Nanomedicine | 1 | 2016 | 6 | 0.030 |
Why?
|
| Infrared Rays | 1 | 2016 | 12 | 0.030 |
Why?
|
| Arteries | 1 | 2016 | 108 | 0.030 |
Why?
|
| Proteomics | 1 | 2018 | 246 | 0.030 |
Why?
|
| Porosity | 1 | 2016 | 63 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2016 | 25 | 0.030 |
Why?
|
| Photosensitizing Agents | 1 | 2016 | 32 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 945 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 10 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 850 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 981 | 0.030 |
Why?
|
| Kupffer Cells | 1 | 2015 | 75 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 54 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2015 | 119 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 61 | 0.030 |
Why?
|
| Carcinogens | 1 | 2016 | 86 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 114 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 82 | 0.030 |
Why?
|
| Peroxynitrous Acid | 1 | 2015 | 55 | 0.030 |
Why?
|
| Tissue Engineering | 1 | 2017 | 212 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Gold | 1 | 2016 | 76 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 282 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Myocardium | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Menopause | 1 | 2015 | 47 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 280 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 149 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2014 | 33 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2016 | 235 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2014 | 18 | 0.030 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 53 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 42 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 67 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2016 | 231 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 64 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2014 | 110 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 62 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 489 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2014 | 54 | 0.030 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2014 | 6 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1515 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 619 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2014 | 71 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2014 | 129 | 0.030 |
Why?
|
| Gastritis | 1 | 2013 | 12 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 376 | 0.030 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2013 | 17 | 0.030 |
Why?
|
| Erythropoiesis | 1 | 2013 | 24 | 0.030 |
Why?
|
| Tyrosine | 1 | 2014 | 196 | 0.030 |
Why?
|
| Parietal Cells, Gastric | 1 | 2013 | 23 | 0.030 |
Why?
|
| Leupeptins | 1 | 2013 | 23 | 0.030 |
Why?
|
| Chemokine CXCL5 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 2013 | 189 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2013 | 11 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 103 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2013 | 137 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 233 | 0.030 |
Why?
|
| Cyclins | 1 | 2013 | 50 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 101 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2013 | 34 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 254 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 100 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 80 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 10 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2013 | 114 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Organophosphorus Compounds | 1 | 2012 | 13 | 0.030 |
Why?
|
| Acylation | 1 | 2012 | 22 | 0.030 |
Why?
|
| Transgenes | 1 | 2012 | 92 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 86 | 0.030 |
Why?
|
| Catalysis | 1 | 2012 | 123 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 164 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 186 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 706 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 320 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 765 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 69 | 0.030 |
Why?
|
| Endonucleases | 1 | 2011 | 10 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 572 | 0.030 |
Why?
|
| Aorta | 1 | 2013 | 316 | 0.020 |
Why?
|
| Leukocyte Disorders | 1 | 2011 | 1 | 0.020 |
Why?
|
| Liposomes | 1 | 2012 | 107 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 142 | 0.020 |
Why?
|
| Endoribonucleases | 1 | 2011 | 22 | 0.020 |
Why?
|
| CD36 Antigens | 1 | 2011 | 9 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2011 | 85 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2013 | 434 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2013 | 241 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2013 | 313 | 0.020 |
Why?
|
| Middle Aged | 3 | 2015 | 21147 | 0.020 |
Why?
|
| Caspases | 1 | 2011 | 194 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2011 | 100 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 98 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 343 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2007 | 45 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 343 | 0.020 |
Why?
|
| Apolipoprotein B-100 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2007 | 31 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2007 | 81 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2007 | 162 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 420 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2007 | 112 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 120 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 246 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4848 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 2334 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 21403 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 7029 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 5717 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5731 | 0.010 |
Why?
|